Annals of esophagus最新文献_第3页

A unique case of black esophagus and black stomach 一例独特的黑食管和黑胃病例

Annals of esophagus Pub Date : 2022-01-01 DOI: 10.21037/aoe-22-35

M. Kalas, Ihsan Al Bayati

引用次数: 0

Dedicated services for Barrett’s esophagus—a survey and service assessment of provision in United Kingdom hospitals Barrett食管的专门服务——英国医院提供服务的调查和评估

Annals of esophagus Pub Date : 2022-01-01 DOI: 10.21037/aoe-22-12

Elizabeth Ratcliffe, Yong Liew, J. Kuan, Yeson Kim, M. Kopczynska, J. Britton, J. Mclaughlin, Shaheen Hamdy, Y. Ang

{"title":"Dedicated services for Barrett’s esophagus—a survey and service assessment of provision in United Kingdom hospitals","authors":"Elizabeth Ratcliffe, Yong Liew, J. Kuan, Yeson Kim, M. Kopczynska, J. Britton, J. Mclaughlin, Shaheen Hamdy, Y. Ang","doi":"10.21037/aoe-22-12","DOIUrl":"https://doi.org/10.21037/aoe-22-12","url":null,"abstract":"Background: Specialist services in medicine are increasingly recognised as gold standard care, in gastroenterology, studies of Barrett’s esophagus (BE) suggest dedicated services show better adherence to surveillance protocols and concomitant dysplasia detection. The aim of this study was to gain insight into the BE practice in UK hospitals. Methods: Adult endoscopy units in the UK were contacted via phone or email and asked to complete a 9-question survey about their BE service. Results: Two hundred and sixty-five units (~95%) were contacted with a response rate of 61.9% (164/265), 56.3% (85/151) reported a dedicated BE service. Having a dedicated BE service was associated with the use of high-resolution white light (92.9% vs . 71.2%, P=0.001) and acetic acid (83.5% vs . 48.5%, P<0.001) and the availability of advanced endoscopic therapies such as radiofrequency ablation (43.5% vs . 19.7%, P=0.004). Trusts which reported a dedicated BE endoscopy service were more likely to have a dedicated BE clinic (52.9% vs . 16.7%, P<0.001) and a named BE lead (85.9% vs . 31.8%, P<0.001). Conclusions: Dedicated services for BE are available in the UK and associated with quality indicators, work is needed to determine the efficacy and efficiency of this model of service. carries a with a been one of the of need by Cancer Research UK and they estimate 59% of esophageal cancers are preventable (4). In order to detect dysplasia and early cancers, international and national guidelines advise regular surveillance endoscopy procedures performed every 2–5 years, during which visible abnormalities are targeted for biopsy and quadrantic biopsies every 1–2 cm (Seattle protocol biopsies) are performed to try to detect early changes (5-7). Retrospective studies have shown there are outcomes for patients on surveillance (8) and adherence to Seattle protocol leads greater for the detection of dysplasia (9).","PeriodicalId":72217,"journal":{"name":"Annals of esophagus","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47375220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How well are patients with Barrett’s esophagus treated in the UK: the gap in management 英国巴雷特食管患者的治疗效果如何：管理上的差距

Annals of esophagus Pub Date : 2022-01-01 DOI: 10.21037/aoe-22-31

J. Jankowski, Sharon B. Love

引用次数: 0

Dedicated services for Barrett’s esophagus Barrett食管专用服务

Annals of esophagus Pub Date : 2022-01-01 DOI: 10.21037/aoe-22-25

Rafael C Katayama, F. Herbella

引用次数: 1

2021 NCC/CATS/CSTCVS/STM expert consensus on perioperative immunotherapy for esophageal cancer 2021 NCC/CATS/CSTCVS/STM食管癌症围术期免疫治疗专家共识

Annals of esophagus Pub Date : 2021-09-01 DOI: 10.21037/aoe-21-64

X. Kang, J. Qin, Rui-xiang Zhang, Zhen Wang, Qingfeng Zheng, Yong Li, Jian‐ping Xu, Jing Huang, Xin Wang, Z. Hui, L. Xue, Y. Mao, Yin Li, Jie He, Chun Chen, Haiquan Chen, Ke-Neng Chen, Long-Qi Chen, M. Fu, Junke Fu, Qing-Hui Geng, Taiqian Gong, Shiping Guo, Yongtao Han, Yi He, Jian Hu, Hongjing Jiang, Jie Jiang, Yue-Feng Jiang, Mingqiang Kang, Jianqun Ma, Shaohua Ma, Y. Liao, Hecheng Li, Shan Li, Zhigang Li, Shuoyan Liu, Yang Liu, G. Qiao, L. Tan, Hui Tian, Gaofeng Zhao, Jun Zhao, S. Zheng, Yong’an Zhou, Magnus Nilsson, F. Schlottmann, R. Rosati, Cascinu Stefano, P. Chiu, N. Newman, N. Hirahara, Dae Joon Kim, R. Mehta, K. Johung, M. Cecchini, S. Lloyd, K. Meredith

{"title":"2021 NCC/CATS/CSTCVS/STM expert consensus on perioperative immunotherapy for esophageal cancer","authors":"X. Kang, J. Qin, Rui-xiang Zhang, Zhen Wang, Qingfeng Zheng, Yong Li, Jian‐ping Xu, Jing Huang, Xin Wang, Z. Hui, L. Xue, Y. Mao, Yin Li, Jie He, Chun Chen, Haiquan Chen, Ke-Neng Chen, Long-Qi Chen, M. Fu, Junke Fu, Qing-Hui Geng, Taiqian Gong, Shiping Guo, Yongtao Han, Yi He, Jian Hu, Hongjing Jiang, Jie Jiang, Yue-Feng Jiang, Mingqiang Kang, Jianqun Ma, Shaohua Ma, Y. Liao, Hecheng Li, Shan Li, Zhigang Li, Shuoyan Liu, Yang Liu, G. Qiao, L. Tan, Hui Tian, Gaofeng Zhao, Jun Zhao, S. Zheng, Yong’an Zhou, Magnus Nilsson, F. Schlottmann, R. Rosati, Cascinu Stefano, P. Chiu, N. Newman, N. Hirahara, Dae Joon Kim, R. Mehta, K. Johung, M. Cecchini, S. Lloyd, K. Meredith","doi":"10.21037/aoe-21-64","DOIUrl":"https://doi.org/10.21037/aoe-21-64","url":null,"abstract":"Xiaozheng Kang, Jianjun Qin, Ruixiang Zhang, Zhen Wang, Qingfeng Zheng, Yong Li, Jianping Xu, Jing Huang, Xin Wang, Zhouguang Hui, Liyan Xue, Yousheng Mao, Yin Li, Jie He, Chun Chen, Haiquan Chen, Ke-Neng Chen, Long-Qi Chen, Maoyong Fu, Junke Fu, Qing Geng, Taiqian Gong, Shiping Guo, Yongtao Han, Yi He, Jian Hu, Hongjing Jiang, Jie Jiang, Yuequan Jiang, Mingqiang Kang, Jianqun Ma, Shaohua Ma, Yongde Liao, Hecheng Li, Shanqing Li, Zhigang Li, Shuoyan Liu, Yang Liu, Guibin Qiao, Lijie Tan, Hui Tian, Gaofeng Zhao, Jun Zhao, Shiying Zheng, Yongan Zhou, Magnus Nilsson, Francisco Schlottmann, Riccardo Rosati, Cascinu Stefano, Philip Wai-yan Chiu, Neil B. Newman, Noriyuki Hirahara, Dae Joon Kim, Rutika Mehta, Kimberly L. Johung, Michael Cecchini, Shane Lloyd, Kenneth Meredith","PeriodicalId":72217,"journal":{"name":"Annals of esophagus","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46398501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Endoscopic therapy in Barrett’s Esophagus: in evolution 巴雷特食管的内镜治疗:发展中

Annals of esophagus Pub Date : 2021-08-10 DOI: 10.21037/aoe-21-55

M. Desai

引用次数: 0

Considerations in the management of gastroesophageal reflux disease in the morbidly obese 对病态肥胖患者胃食管反流病治疗的思考

Annals of esophagus Pub Date : 2021-07-29 DOI: 10.21037/aoe-21-20

K. Seeras, Johan Campbell, A. Pryor

引用次数: 1

Update on ablative therapy for Barrett’s related dysplasia 巴雷特相关发育不良的消融治疗最新进展

Annals of esophagus Pub Date : 2021-07-05 DOI: 10.21037/aoe-2020-36

S. Freund, A. Probst, H. Messmann

引用次数: 0

The cutting edges of esophageal cancer management 食管癌症治疗的前沿

Annals of esophagus Pub Date : 2021-06-25 DOI: 10.21037/AOE-2020-19

R. Rosati

引用次数: 0

Neoadjuvant treatment in esophageal cancer—established treatments and new developments reviewed 食管癌新辅助治疗的现状及新进展

Annals of esophagus Pub Date : 2021-06-25 DOI: 10.21037/AOE-2020-05

B. Mostert, A. Gaast

{"title":"Neoadjuvant treatment in esophageal cancer—established treatments and new developments reviewed","authors":"B. Mostert, A. Gaast","doi":"10.21037/AOE-2020-05","DOIUrl":"https://doi.org/10.21037/AOE-2020-05","url":null,"abstract":"As the majority of patients experiences locoregional relapse and/or distant metastasis even after radical resection of esophageal cancer, many efforts have been made and are ongoing to identify the optimal multimodality treatment strategy. The true benefit and harm of neoadjuvant therapy including chemotherapy, radiotherapy or the combination, is still difficult to interpret given the heterogeneity in patient and tumor characteristics. Nonetheless, neoadjuvant chemoradiation with weekly carboplatin and paclitaxel (the CROSS regimen) is considered standard of care for squamous cell carcinoma in Europe. Definitive chemoradiation is considered an equal alternative in the United States. For adenocarcinoma, preoperative chemoradiation with a platinum and 5FU or the CROSS regimen and peri-operative chemotherapy with a platinum and 5FU or the FLOT (fluorouracil, leukovorin, oxaliplatin and docetaxel) regimen are all options. New developments in systemic anti-tumor therapy will most likely involve dual anti-HER2 inhibition or novel anti-HER2 antibody-drug conjugates for adenocarcinoma. Immunotherapy monotherapy in an unselected patient population does not seem to be as effective in esophageal cancer as it is in other cancer types. However, when we can correctly identify the subset of patients which does benefit from this treatment by employing new predictive markers, or find an effective synergistic combination of immunotherapy with chemotherapy and/ or radiotherapy, immunotherapy could still improve patient outcome in the future.","PeriodicalId":72217,"journal":{"name":"Annals of esophagus","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48685566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1